Thomas Young, MD
Gastroenterology · Knoxville, TNNPI 1053493791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,900 of the $20,272 with a category attached, or 73.5%. AbbVie accounts for 86.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $8,928 and has fallen 88.5% since, to $1,027 in 2025. Among gastroenterology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $62.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$642
- Ardelyx, Inc.$325
- Bristol Myers Squibb$256
- Takeda Pharmaceuticals U.S.A., Inc.$240
- Gilead$185
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$14,90073%
- Food & beverage$5,32526%
- Education$310%
- Gifts$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $17,460 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $642 |
| Ardelyx, Inc. | 16 | $325 |
| Bristol Myers Squibb | 16 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $240 |
| Gilead | 8 | $185 |
| Ironwood Pharmaceuticals, Inc | 7 | $117 |
| Nestle Healthcare Nutrition Inc. | 4 | $77 |
| Merck | 3 | $74 |
| Johnson & Johnson | 4 | $72 |
| Aimmune Therapeutics, Inc. | 4 | $72 |
| Medtronic | 3 | $69 |
| Celltrion USA Inc. | 3 | $69 |
| Pfizer | 4 | $61 |
| Intercept Pharmaceuticals, Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Braintree Laboratories, Inc. | 2 | $37 |
| Organon | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| QOL Medical, LLC | 1 | $27 |
| Intra-sana Laboratories | 1 | $26 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Endogastric Solutions, Inc | 2 | $21 |
| Amgen | 1 | $20 |
| Olympus America Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Axonics, Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$14,900
How this compares
$20,272 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $565,490 |
| LinzessLinaclotide | 118 | $120,006 |
| XifaxanRifaximin | 18 | $58,620 |
| IbsrelaTenapanor Hcl | 16 | $31,177 |
| TrulancePlecanatide | 14 | $19,321 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 102 | $16,176 |
| Colesevelam Hcl | 105 | $13,123 |
| Omeprazole | 762 | $12,855 |
| Colestipol Hcl | 67 | $11,247 |
| Budesonide ErBudesonide | 11 | $10,103 |
| Budesonide DrBudesonide | 39 | $7,213 |
| AprisoMesalamine | 13 | $6,527 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 92 | $6,154 |
| Dexlansoprazole DrDexlansoprazole | 29 | $5,788 |
| Mesalamine ErMesalamine | 29 | $4,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $72 | $565,49021 claims |
| AbbVieLinzess | $17,460 | $120,006118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso | $642 | $84,46845 claims |
| Ardelyx, Inc.Ibsrela | $325 | $31,17716 claims |
| Braintree Laboratories, Inc.Sutab | $37 | $16,176102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Knoxville
- Raj NarayaniKnoxville$204K
- Carlos RollhauserKnoxville$144K
- Meade EdmundsKnoxville$21K
- Jeffrey GilbertKnoxville$14K
- Robert PollackKnoxville$14K
- Jeffrey BrownKnoxville$14K
- Ramanujan SamavedyKnoxville$12K
- Shaker BarhamKnoxville$11K
- John MooreKnoxville$11K
- David SchwartzNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.